ACUVUE OASYS: Developed in strategic partnership with Transitions Optical, this first-of-its-kind contact lens seamlessly adapts to changing light conditions while providing all-day soothing vision.
Johnson & Johnson Vision today announced ACUVUE OASYS with Transitions was issued a medical device license by Health Canada. ACUVUE OASYS with Transitions Light Intelligent Technology is a first-of-its-kind contact lens in Canada that offers benefits beyond vision correction by reducing exposure to bright light both indoors and outdoors.1,4 These lenses are indicated for the attenuation of bright light.
These contact lenses function by quickly and seamlessly adjusting from clear to dark in response to changing light conditions, balancing the amount of light entering the eye including filtering blue light and blocking harmful UV rays. ACUVUE OASYS with Transitions has created and defined an entirely new category of contact lenses that will help address unmet needs for patients.
“ACUVUE OASYS with Transitions is the result of more than a decade of product development and numerous clinical trials involving more than 1,000 patients,” said Ted Lachmansingh, Canada Business Director, Johnson & Johnson Vision. “This first-of-its-kind contact lens was born out of deep research into consumer lifestyle needs and provides wearers with a solution to help manage light in their modern, active lives.”
A range of everyday lighting situations, from artificial light to UV rays, can impact eye comfort and vision.7,8,9ACUVUE OASYS with Transitions actively adapts to light conditions encountered throughout the day to balance the amount of light hitting the eye, and helps eyes adjust to changing light better than they would on their own.3,4
This strategic partnership between Johnson & Johnson Vision Care, Inc. and Transitions Optical combines the respective strengths of each company. While ACUVUE is the world leader in contact lenses, Transitions Optical is the leading provider of photochromic (smart adaptive) lenses worldwide. Both companies are working to research and deliver best-in-class vision care innovations.
This regulatory milestone is an important step toward achieving Johnson & Johnson’s vision of helping people see better, connect better, and live better. The two-week reusable contact lens will be commercially available in the first half of 2019. —CNW
